Cancer news - the latest biotech news from Labiotech.eu

Crescendo Biologics raises $32M and expands cancer trial

Jim Cornall — Tue, 25 Jul 2023 08:21:48 +0000

Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […]

The post Crescendo Biologics raises $32M and expands cancer trial appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Sarcoma research: is a breakthrough in sight?

Roohi Mariam Peter — Mon, 24 Jul 2023 14:24:40 +0000

Among the rarest forms of cancers, sarcomas develop in the bones and connective tissues that support structures in the body like blood vessels, nerves and joints. This year, around 13,400 new cases of soft tissue sarcomas are estimated to be diagnosed in the U.S. alone, according to the American Cancer Society. As July marks Sarcoma […]

The post Sarcoma research: is a breakthrough in sight? appeared first on Labiotech.eu.

CatalYm shows importance of GDF-15 in tumor immunotherapy resistance

Jim Cornall — Thu, 20 Jul 2023 17:00:00 +0000

CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […]

The post CatalYm shows importance of GDF-15 in tumor immunotherapy resistance appeared first on Labiotech.eu.

Endometrial cancer drug receives breakthrough therapy designation in China

Jim Cornall — Thu, 20 Jul 2023 15:36:06 +0000

HUTCHMED (China) Limited has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based […]

The post Endometrial cancer drug receives breakthrough therapy designation in China appeared first on Labiotech.eu.

Moleculin issues acute myeloid leukemia drug data

Jim Cornall — Wed, 19 Jul 2023 09:24:12 +0000

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with drug candidates targeting hard-to-treat tumors and viruses, has published data from its completed MB-105 European phase 1 clinical trial assessing the safety and efficacy of annamycin as a single agent for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). ‘Results of a […]

The post Moleculin issues acute myeloid leukemia drug data appeared first on Labiotech.eu.

TME Pharma provides positive glioblastoma trial results

Jim Cornall — Fri, 14 Jul 2023 09:30:00 +0000

TME Pharma N.V. has announced a positive clinical update on the best response to therapy, reporting one patient achieving complete response in the GLORIA expansion arm evaluating NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab, in first-line glioblastoma. TME Pharma is a biotechnology company focused on developing novel […]

The post TME Pharma provides positive glioblastoma trial results appeared first on Labiotech.eu.

Calliditas reveals ‘encouraging results’ from head and neck cancer trial

Jim Cornall — Fri, 14 Jul 2023 08:46:44 +0000

Calliditas Therapeutics AB has announced interim data from its proof-of-concept phase 2 trial in patients with squamous cell carcinoma of the head and neck (SCCHN) with its lead NOX 1 and 4 inhibitor product candidate, setanaxib. The analysis reflects encouraging early clinical progression-free survival (PFS) results and is supportive of the presumed anti fibrotic mode […]

The post Calliditas reveals ‘encouraging results’ from head and neck cancer trial appeared first on Labiotech.eu.

ADC Therapeutics pauses clinical trial following patient deaths

Jim Cornall — Wed, 12 Jul 2023 14:00:00 +0000

ADC Therapeutics SA has announced a voluntary pause in the enrollment of new patients in the phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The action was taken by ADC Therapeutics after a recent review of aggregate data […]

The post ADC Therapeutics pauses clinical trial following patient deaths appeared first on Labiotech.eu.

Pfizer kicks $25M into CellCentric

Jim Cornall — Wed, 12 Jul 2023 12:00:00 +0000

U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25 million to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific hematological malignancies, through […]

The post Pfizer kicks $25M into CellCentric appeared first on Labiotech.eu.

Crossbow Therapeutics launches with $80M to target cancer

Jim Cornall — Wed, 12 Jul 2023 09:57:20 +0000

Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding. The round was led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture […]

The post Crossbow Therapeutics launches with $80M to target cancer appeared first on Labiotech.eu.

Immune memory research could lead to next generation of epigenetic drugs

Jim Cornall — Tue, 11 Jul 2023 10:31:34 +0000

A team of researchers has discovered that the memory of the immune system relies on characteristic epigenetic features and a specific 3D arrangement of the DNA in the nucleus of memory cells, allowing for a fast activation of these cells. These features are altered in chronic inflammation diseases like asthma and could be important in […]

The post Immune memory research could lead to next generation of epigenetic drugs appeared first on Labiotech.eu.

Existing cancer drug could be repurposed to fight certain aggressive cancers

Jim Cornall — Mon, 10 Jul 2023 15:00:00 +0000

A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has found that an existing cancer drug could be repurposed to target a subset of cancers that currently lack targeted treatment options and is often associated with poor outcomes.This subset of cancers makes up 15% of all cancers and is especially prevalent in […]

The post Existing cancer drug could be repurposed to fight certain aggressive cancers appeared first on Labiotech.eu.

“Ready-to-use” enzymatically produced cell-free synthetic DNA in mRNA manufacturing

External Contributor — Mon, 10 Jul 2023 14:36:43 +0000

By Ashish Dhir, PhD and Amy Walker, PhD, 4basebio The pace, efficacy and scalability with which the success of mRNA vaccines against COVID-19 was demonstrated opened endless possibilities for mRNA medicine in broad areas of infectious diseases, cancers, protein-encoding replacement therapies. The advantages of RNA medicine are obvious, with the ease and speed of design […]

The post “Ready-to-use” enzymatically produced cell-free synthetic DNA in mRNA manufacturing appeared first on Labiotech.eu.

Making an impact through targeting mRNA

Jim Cornall — Mon, 10 Jul 2023 12:00:00 +0000

Biotech company Molecure develops small molecule therapies that can regulate RNA and underexplored protein targets for the treatment of incurable diseases, including cancer and fibrotic and inflammatory diseases. The company, which was named as one of our 10 biotech companies leading the charge in Poland, told Labiotech that its RNA platform finds small molecules that […]

The post Making an impact through targeting mRNA appeared first on Labiotech.eu.

CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology

Jim Cornall — Fri, 07 Jul 2023 10:43:25 +0000

CytoMed Therapeutics Limited, a Singapore-based biopharma company focused on novel donor cell-based immunotherapies for the treatment of various cancers, has announced that its CAR-gamma delta T cell (CAR-γδ T cell) technology, which it has licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office (USPTO). The patent covers technologies for […]

The post CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology appeared first on Labiotech.eu.

LIfT produces neutrophil-based cell therapy from iPSCs

Jim Cornall — Thu, 06 Jul 2023 10:15:00 +0000

LIfT BioSciences has announced successful proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). The proof-of-concept using iN-LIfT, the company’s second-generation platform, which is derived from iPSCs (a type of cell that has been reprogrammed so it is capable of becoming any type of cell) has shown that the alpha […]

The post LIfT produces neutrophil-based cell therapy from iPSCs appeared first on Labiotech.eu.

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Jim Cornall — Thu, 06 Jul 2023 09:40:00 +0000

Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy. […]

The post AstraZeneca non-small cell lung cancer drug meets primary endpoint appeared first on Labiotech.eu.

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Jim Cornall — Tue, 04 Jul 2023 09:32:25 +0000

Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […]

The post Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment appeared first on Labiotech.eu.

New drug helps prostate cancer patients

Jim Cornall — Tue, 04 Jul 2023 09:13:03 +0000

Researchers at the Paul Scherrer Institute (PSI) in Switzerland have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the PSI, the University Hospital Basel and ETH Zurich is receiving CHF […]

The post New drug helps prostate cancer patients appeared first on Labiotech.eu.

Exeliom Biosciences closes €24M financing for lead candidate

Jim Cornall — Tue, 04 Jul 2023 09:02:23 +0000

Exeliom Biosciences has completed a €24 million ($26 million) Series A to progress the clinical development of its therapeutic pipeline. This includes several clinical trials of EXL01, a novel immunotherapy with applications in cancer and in infectious diseases. This follows on from the initial closing of €7 million ($7.6 million) in 2018, a first extension […]

The post Exeliom Biosciences closes €24M financing for lead candidate appeared first on Labiotech.eu.